Range
Dist6
RSP

RSP

Invesco S&P 500 Equal Weight ETF

$216.87-2.89%
Setup
Near pivot
Buy Zone
$218.62-$229.55
Sector
Exchange Traded Fund
Industry
Exchange Traded Fund
52
Recommendation
Avoid
Avoid

Too many CANSLIM criteria failing.

RSP chart

Loading chart…
Overall Quality52
56
relative strength
45
Weak fund-Q
68
+250% vs avg
88
7/8 checks
91
Exchange Traded Fund

Trade Plan

Avoid
Entry
$218.62
Entry Zone
$218.62-$229.55
Stop / Risk
$201.13
RS Rating
56
Volume confirmed
No
Targets
$262.34 / $273.27

Breakout · IBD Setup

4 ✓ 4 ✗
Entry $218.62–$229.55Stop $201.13Target $262.34 / $273.27
Market regimeRange
Quality52
RS Rating56
Above 50-MA+0.92%
Above 200-MA+4.16%
VolumeWeak
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop

How this came together

52
MarketRange
SetupNear pivot
ConfidenceExperimental · not backtested
Fund-Q45 · Weak
StatusAvoid

Stock Data

52-Week Range182 – 224
Price % Chg YTD13.21%
Price % Chg 4wk2.98%
50-Day Avg Vol7.4 Mil
P/E Ratio—
Market Cap$397B
SectorFinancial
IndustryExchange Traded Fund

Company Fundamentals

EPS % Chg (Qtr)—
Sales % Chg (Qtr)—
EPS Growth 5y—
Sales Growth 5y—
Annual ROE—
Gross Margin—
Operating Margin—
Net Margin—
Debt / Equity—

Setup levels

Current price
$216.87
Pivot
$218.62
Distance to buy
-3%
52-week range
182.11-223.51

Trigger evidence

No active trigger evidence available.
Financial health checks
0/0

Key metrics

Finviz snapshot · value vs. sector median (≥5 peers)

Annual ROE—
Net margin—
Gross margin—
EPS growth q/q—
Sales growth q/q—
Debt / equity—
lower is better

Business quality

45
GradeWeak
EPS rating50
P/E—
Market cap$397B
IndustryExchange Traded Fund

Technical checks

Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Pass
Volumen bestätigt
Fail
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass

IBD / source mentions

No recent IBD mention found for this ticker.

Signal history

Added to list
2026-11-02
Trigger date
—
Days on list
4

Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.